| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Boenisch Sandra | PFO & Treasurer | 630 5TH AVENUE, 20TH FLOOR, NEW YORK | /s/ Sandra Boenisch | 22 Aug 2025 | 0001655366 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVXL | Stock Option (Right to Buy) | Award | $0 | +12,500 | $0.000000 | 12,500 | 20 Aug 2025 | Common Stock | 12,500 | $8.58 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares. |